Interacción de Lemborexant con Metaxalona
Lemborexant con Metaxalona: ambas etiquetas de prescripción advierten sobre esta combinación con el lenguaje más contundente, como una contraindicación, una advertencia en recuadro o la indicación de evitarla.
No combinar sin la orientación de un prescriptor. El lenguaje de la etiqueta que aparece a continuación es el más contundente que usa la FDA.
Qué dicen las etiquetas de la FDA
De la etiqueta de Metaxalona (Metaxalone) · vigente desde 2026-02-03
If concomitant use with another CNS depressant is warranted, closely monitor for signs of respiratory depression and sedation, particularly during treatment initiation and dosage increases.
If concomitant use of metaxalone and another CNS depressant is warranted, closely monitor for signs of respiratory depression and sedation, particularly during treatment initiation and dosage increases.
Depressants If concomitant use of Metaxalone Tablets, 640 mg and another CNS depressant is warranted, closely monitor for signs of respiratory depression and sedation, particularly during treatment initiation and dosage modification.
Due to the additive pharmacologic effect, concomitant use of Metaxalone Tablets, 640 mg with other CNS depressants may increase the risk of sedation and respiratory depression [see Warnings and Precautions (5.2) ].
Central Nervous System (CNS) Depression : Metaxalone Tablets, 640 mg may impair mental and/or physical abilities required for the performance of hazardous tasks, such as operating machinery or driving a motor vehicle, and may enhance the effects of other CNS depressants including alcohol.
De la etiqueta de Lemborexant (DAYVIGO) · vigente desde 2025-02-24
CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment.
Risk increases with dose and use with other central nervous system (CNS) depressants.
Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment.
Dosage adjustments of DAYVIGO and of concomitant CNS depressants may be necessary when administered together because of potentially additive effects.
CNS Depressant Effects and Daytime Impairment DAYVIGO is a central nervous system (CNS) depressant that can impair daytime wakefulness even when used as prescribed.
¿Toma algo más además de estos dos? Las interacciones se acumulan. Compruebe toda su lista de una vez; se queda en su navegador.
Abrir en el verificadorNo es un consejo médico. Interaction Checker cita el texto de las etiquetas de la FDA y las hojas informativas de los NIH. Que una interacción sea importante en su caso depende de las dosis, el momento de las tomas, la función renal y hepática y otras afecciones. Confírmelo con un farmacéutico o un prescriptor.